文献速递心血管PET

心肌18FDG摄取与免疫抑制对心肌病预后的影响

Impact of 18FDG-Avidity and Immunosuppression on Idiopathic and Genetic Cardiomyopathies
RSS 订阅 · Circulation: Cardiovascular Imaging

本研究回顾性纳入372例同时接受18FDG-PET和心肌病基因检测的患者,其中142例存在心肌18FDG摄取。结果显示心肌18FDG摄取与心衰复合终点及心律失常复合终点风险增加相关,但多变量调整后关联不显著。在无明确心脏结节病的患者中,免疫抑制治疗未降低心衰或心律失常复合终点风险。

要点

  • 心肌18FDG摄取在基因阳性与基因阴性患者中的预后意义相似
  • 心肌18FDG摄取不等于临床有意义的活动性炎症,不宜据此常规启动免疫抑制
  • 无明确心脏结节病时,18FDG摄取对心衰和心律失常风险的独立预测价值有限

核心结论

  • 在无明确心脏结节病的患者中,心肌单独18FDG摄取与心衰或心律失常风险无显著独立关联
  • 免疫抑制治疗未改变存在心肌18FDG摄取患者的疾病进程

研究设计与样本

  • 多中心回顾性研究,纳入所有同时接受18FDG-PET和心肌病基因检测的患者
  • 排除急性心肌炎、活检证实的结节病或心外18FDG摄取患者,最终纳入372例
  • 采用生存分析、Cox比例风险模型及逆概率处理加权分析

关键影像表现/征象

  • 372例患者中142例存在心肌18FDG摄取,18FDG摄取患者中遗传性心肌病患病率为12%
  • 18FDG阴性患者遗传性心肌病患病率为18%,差异无统计学意义

诊断标准与关键数值

  • 未调整分析中,18FDG摄取与心衰复合终点风险增加相关,HR为1.69,95%CI为1.04-2.75,P=0.034
  • 未调整分析中,18FDG摄取与心律失常复合终点风险增加相关,HR为1.63,95%CI为1.1-2.4,P=0.014
  • 多变量调整后,18FDG摄取与心衰及心律失常复合终点的关联均不具统计学显著性
  • 逆概率处理加权后,免疫抑制组与未免疫抑制组在心衰及心律失常复合终点上无显著差异

临床应用与阅片要点

  • 阅片报告应客观描述心肌18FDG摄取范围与程度,避免直接等同于活动性心肌炎
  • 对基因阴性且无心脏结节病依据的18FDG摄取病例,应谨慎评估免疫抑制指征

局限性

  • 回顾性研究设计,存在选择偏倚和混杂因素可能
  • 18FDG-PET检查的禁食和代谢准备标准化程度未在摘要中详述
英文原文(摘要)· 点击展开

Circulation: Cardiovascular Imaging, Ahead of Print. BACKGROUND:Myocardial18fluorodeoxyglucose (18FDG)-avidity is frequently seen in patients with genetic cardiomyopathy, as well as a growing “idiopathic18FDG-avidity” group of genotype-negative patients who do not clearly have cardiac sarcoidosis. The prognostic implications of18FDG-avidity in patients with and without genetic cardiomyopathy, and the effects of immunosuppression in the latter, remain uncertain.METHODS:This multicenter, retrospective study included all patients who were referred for both18FDG-PET and cardiomyopathy genetic testing. Patients with acute myocarditis, biopsy-proven sarcoidosis, or extracardiac18FDG-avidity were excluded. We investigated heart failure (HF) composite (left ventricular assist device, heart transplant, HF hospitalization, or death) and arrhythmia composite (sustained ventricular arrhythmias [ventricular tachycardia/VF], atrioventricular block, or death) outcomes using survival analysis, including Cox proportional hazards modeling and inverse probability of treatment weighting.RESULTS:Among 372 patients, 142 (38%) were18FDG-avid. The prevalence of genetic cardiomyopathy among18FDG-avid patients (12%) was similar to that of18FDG-negative patients (18%;P=0.11). Unadjusted,18FDG-avidity was associated with an increased risk of HF composite (hazard ratio, 1.69 [95% CI, 1.04–2.75];P=0.034) and arrhythmia composite (hazard ratio, 1.63 [95% CI, 1.1–2.4];P=0.014) outcomes compared with18FDG-negative patients. However, these associations were not statistically significant after multivariable adjustment, nor were there significant differences in18FDG-associated risks in patients with genetic cardiomyopathy versus genotype-negative patients. After inverse probability of treatment weighting, immunosuppression of18FDG-avid patients (n=49) was not associated with a reduction in HF or arrhythmia composite outcomes compared with those who were not immunosuppressed (n=93).CONCLUSIONS:Myocardial-only18FDG-avidity is not significantly associated with HF or arrhythmia risk in patients who do not clearly have cardiac sarcoidosis (including those with genetic cardiomyopathy). Immunosuppression therapy does not seem to modify the disease course, suggesting that not all myocardial18FDG uptake reflects clinically significant inflammation.

来源:Circulation: Cardiovascular Imaging,查看原文。版权归原作者所有。

引用

  1. Circulation: Cardiovascular Imaging:Impact of 18FDG-Avidity and Immunosuppression on Idiopathic and Genetic Cardiomyopathies

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。